The Board of Directors of Laurus Labs Limited (LAURUSLABS) at its meeting held on Thursday, i.e. April 29, 2021 has recommended payment of third interim dividend of Rs. 0.8 per equity share. The Board Meeting commenced at 1.30 PM and concluded at 2.30 PM.
Laurus Labs Quarterly Result
The company reported a nearly three-fold jump in consolidated net profit to Rs 296.92 crore for the fourth quarter ended March 31, 2021 on the back of robust performance in all divisions. The total revenue increased 68 per cent at ₹1,412 crore.
Similar Posts
- Tata Investment Corporation Declares Dividend of Rs 24
- Visaka Industries Ltd Declares Final Dividend of Rs 10
Laurus Labs Dividend Record Date
The company in its letter has informed the exchanges that it has fixed 12 May 2021 as the Record date. Further, the declared dividend will be paid on or after May 19, 2021.
To receive dividend, you must have shares in your demat account on record date. Hence, you should buy shares before ex-dividend date. Note – In other words, if you buy shares on ex-dividend date, you will not be eligible to receive dividend. So, Bookmark our website for latest and upcoming dividend announced by companies in 2021.
Moreover, Here is the copy of statement, the company has sent to the exchanges:
Kindly be informed that the Board of Directors of the Company in their meeting held on April 29, 2021 have approved for the payment of 3rd interim dividend of 80 Paise (40%) per equity share of Rs. 2/- each, for the Financial Year 2020-21. The Dividend amount will be paid on or after May 19, 2021.
Important Dates
- Company – Laurus Labs Ltd
- Script Name – LAURUSLABS (NSE) and 540222 (BSE)
- Dividend Amount – 0.8 Rs Per Share
- Dividend Type – 3rd Interim
- Ex-Dividend Date – 11 May 2021
- Record Date – 12 May 2021
- Payment Date – On or after May 19, 2021.
Also, you can find more information about Laurus Labs Limited on National Stock Exchange and Moneycontrol – Laurus Labs is an Indian pharmaceutical company headquartered in Hyderabad. Its focus areas include active pharma ingredients, finished dosage forms, synthesis and biotechnology.
